Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese”Giuseppe Mele, Domenico Pastore, Anna Pia Falcone et al.|Leukemia & lymphoma/Leukemia and lymphoma|2023Cited by 2
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID StudyNicola Sgherza, Pellegrino Musto, Olga Battisti et al.|Pharmaceuticals|2025Cited by 2
Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)Enrica Antonia Martino, Federico Vozzella, Raffaella Pasquale et al.|Blood|2024Cited by 0
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica PuglieseNicola Di Renzo, Pellegrino Musto, Emanuela Resta et al.|Annals of Hematology|2025Cited by 0
Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studiesCatherine Thiéblemont, Paolo Ghia, Emmanuelle Tchernonog et al.|Blood|2025Cited by 0